Conclusions and clinical relevance: The established marker set contains peptides related to tubulointerstitial infiltration seen in acute rejection. The set of urinary peptide markers will be used for

early diagnosis of acute kidney allograft rejection marker in a multicenter phase III prospective study.”
“The concurrent problems of research sustainability and decreased clinician involvement with medical device development can be jointly addressed through a novel, multidisciplinary solution. The University of Rochester Cardiovascular Device Design Program is a sustainable program in medical device design supported through a collaboration between the Schools of Medicine and Engineering. This article provides a detailed description of the motivation for starting the program, the current structure of the program, the methods of financial sustainability, Cisplatin order and the direct impact it intends to have on JSH-23 the national vascular surgery community. The further expansion of this program and encouragement for development of similar programs throughout the country aims to address many of our current challenges in both research funding and device development education. (J Vasc

Surg 2013;57:576-82.)”
“Purpose: In this cross-sectional pilot study we set out to discover a non-invasive biomarker that could distinguish steroid-resistant nephrotic syndrome (SRNS) from steroid-sensitive nephrotic syndrome (SSNS).

Experimental design: Urine and clinical data were collected from patients with idiopathic nephrotic syndrome and healthy controls. Using SELDI-TOF-MS, we identified an 11-fold upregulated

13.8 kDa fragment of alpha 1-B glycoprotein (A1BG) in urine in SRNS. To validate our findings, A1BG was detected by Western blot. Creatinine was measured and transformed to glomerular filtration rate (GFR) by the new Schwartz formula and classified to chronic kidney disease (CKD) stage. p-Values were determined by unpaired t-test and Mann-Whitney rank sum test. Microalbumin was also measured to determine albumin/creatinine ratios.

Results: The 13.8 kDa A1BG was present in 7 of 19 patients with SRNS; but absent in all SSNS (n = 15) and controls (n = 10). The A1BG(+) whatever patients had lower GFR than A1BG(-) patients (p<0.009) and tended to have higher CKD stage.

Conclusion and clinical relevance: The 13.8 kDa A1BG fragment had a high discriminatory power for steroid resistance in pediatric nephrotic syndrome, but is only present in a subset of patients. Additional longitudinal studies are required to determine the usefulness of this biomarker as a non-invasive predictive marker of therapeutic response.”
“Suture-mediated closure devices are increasingly used for closure of large arteriotomies, such as those required for endovascular aortic repair. One of the commonly encountered situations is persistent arteriotomy oozing after successful closure requiring manual compression.